

United States Patent and Trademark Office



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION.NO.
10/007,450	11/05/2001	Douglas F. Covey	WSHU 2036.1	3348.
321 52 759	90 09/10/2003			
SENNIGER POWERS LEAVITT AND ROEDEL ONE METROPOLITAN SQUARE 16TH FLOOR			EXAMINER	
			QAZI, SABIHA NAIM	
ST LOUIS, MO	63102		ART UNIT	PAPER NUMBER
			1616	~
			DATE MAILED: 09/10/2003	8

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 10/007,450 COVEY, DOUGLAS F. Examin r Sabiha Qazi The MAILING DATE of this communication appears on the cov r sh t with th correspondence address					
Office Action Summary Examin r Sabiha Qazi The MAILING DATE of this communication appears on the cov r sh t with th correspondence address					
Sabiha Qazi The MAILING DATE of this communication appears on the cov r sh t with th correspondence address					
The MAILING DATE of this communication appears on the cov r sh t with th correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on <u>11/8/01</u> .					
2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.	i				
Disposition of Claims					
4) Claim(s) <u>1-51</u> is/are pending in the application.					
4a) Of the above claim(s) 1-35 and 46-51 is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) ☐ Claim(s) <u>36-45</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the effect of the patient of					
* See the attached detailed Office action for a list of the certified copies not received.					
 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application a) ☐ The translation of the foreign language provisional application has been received. 	11).				
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 6) Other:					

Application/Control Number: 10/007,450

Art Unit: 1616

Claims 1-51 are pending. Pre-amendments are entered. Claims 36-35 are examined; others are withdrawn from consideration as non-elected invention.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-32 drawn to a compound of formula in claim 1,
- II. Claims 33-35 drawn to a process for conferring cytoprotection on a population of cells.
- III. Claims 36-45 drawn to a compound of formula in claim 35.
- IV. Claims 46-51 drawn to a compound of formula in claim 45

 The inventions are distinct, each from the other because of the following reasons:

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and the search required for Group I is not required for Group II or any other group, and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Steroidal compounds as presently claimed encompass hundreds of thousands of compounds which require a burdensome classification, and/or bibliographic, manual and computer database search. In

Application/Control Number: 10/007,450

Art Unit: 1616

addition to invention as in claim 33 where a process for conferring cytoprotection on a population of cells is itself a separate invention.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from the elected group for the search purposes even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patent ably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

During a telephone conversation with Attorney on 3/17/03 a provisional election was made with traverse to prosecute the invention of group III, claims 36-45. Applicant in replying to this Office action must make affirmation of this election. Claims 1-35 and 46-51 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a nonelected invention, the inventor ship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an Application/Control Number: 10/007,450

Art Unit: 1616

inventor of at least one claim remaining in the application. Any amendment of inventor ship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claim 36 and 45 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 45 depends on claim 42. Claim 45 is drawn to a process of claim 42. Claim 42 is not a process claim. A correction is suggested.

It is unclear what is the meaning of non-fused polycyclic, hydrophobic substituent in the definition of R1 in claim 36.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 36-45 rejected under 35 U.S.C. 102(b) as being anticipated by Ismail (Eur. J. Med Chem. (1995); (IDS paper no. 6). See compound 9A and 9B on page 425.

Application/Control Number: 10/007,450 Page 5

Art Unit: 1616

The Examiner has noted the proviso in claim 36. Applicant is requested to disclose the reference or any reason for the proviso.

The elected species was compound of claim 43 when R1 is an adamantly group. Elected species should be disclosed single compound. Species election was not proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Naim Qazi whose telephone number is 703-305-3910. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 703-308-4628. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

September 8, 2003,

SABIHA QAZI, PH.D PRIMARY EXAMINER